Metastatic prostate cancer
Conditions
Interventions
Observations group:none
Sponsors
The Second Hospital of Tianjin Medical University
Eligibility
Sex/Gender
Male
Age
40 Years to 90 Years
Inclusion criteria
Inclusion criteria: 1.The patient underwent prostate biopsy and was pathologically diagnosed as adenocarcinoma (including acinar adenocarcinoma, ductal adenocarcinoma, and intraductal carcinoma); 2.The clinical stages were M1 (CT, ECT, PET-CT); 3. Patients receiving ADT after diagnosis; 4. Patients with regular follow-up and timely detection of testosterone, free testosterone and PSA according to the study protocol; 5. The patient had no history of other malignant tumors of urinary system; 6. Patient's medical records and follow-up data were complete.
Exclusion criteria
Exclusion criteria: 1.Prostate cancer patients with other primary tumors; 2. The pathological diagnosis was urothelial origin, intraductal carcinoma, sarcoma, and prostate neuroendocrine carcinoma; 3. Patients taking other anti-tumor drugs during ADT treatment; 4. Patients receiving radiotherapy and/or chemotherapy during ADT treatment; 5. The patient is diagnosed with a neuropsychiatric disease or the use of drugs that may affect the central nervous system during treatment; 6. The patient is diagnosed with hepatitis B, AIDS, tuberculosis and other infectious diseases; 7. Patients with stroke, coronary heart disease, chronic renal insufficiency, chronic liver insufficiency and other major diseases; 8. The patient is complicated with systemic metabolic diseases such as thyroid, adrenal, blood system and pituitary gland
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| free testosterone; | — |
Secondary
| Measure | Time frame |
|---|---|
| Prostate-specific antigen; | — |
Countries
China
Contacts
Public ContactWen Simeng
The Second Hospital of Tianjin Medical University
Outcome results
None listed